Mesothelioma Cancer News Feeds From Google
Bayer ADC fails pivotal mesothelioma trialFierceBiotechA pivotal trial of Bayer's antibody-drug conjugate (ADC) anetumab ravtansine has missed its primary endpoint. The drug failed to improve progression-free survival in mesothelioma patients, causing the stocks of Bayer's collaborators ImmunoGen and ...
Bayer misses in mid-stage mesothelioma trialBioPharma DiveBayer's anetumab ravtansine (BAY 949343) has missed its primary endpoint of progression-free survival as a second-line monotherapy in 248 patients with recurrent malignant pleural mesothelioma (MPM), a cancer linked with asbestos. Safety and ...and more »